Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.

Ventilator Associated Pneumonia Clinical Trial

Official title:

Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel on the Early Adaptation of Antimicrobial Therapy in ICU Patients With Severe Pneumonia. A Prospective Multicentric Observational Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05624684
• Other study ID #: MORICUP-PCR study
• Status: Completed
• Start date: February 3, 2023
• Est. completion date: February 22, 2024

Study information

• Verified date: February 2024
• Source: Avicenna Military Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to assess the diagnostic performance of multiplex respiratory PCR (PCR-RM) compared to standard microbiological tests and its potential impact on the early adaptation of antibiotic treatment in intensive care patients with severe pneumonia.

Description:

This is a prospective, observational, multicenter ICU study. Adult patients with severe pneumonia requiring invasive mechanical ventilation will be included. Severe pneumonia consists of 3 categories of pneumonia: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-acquired pneumonia (VAP). The microbiological testing will be performed before antibiotic initiation on tracheobronchial aspirations, protected distal sampling, or mini-bronchoalveolar lavage as part of routine care. No additional samples will becollected for this study. Respiratory samples will be simultaneously tested by conventional microbiological techniques and multiplex respiratory PCR [PCR-RM] (BIOFIRE® FILMARRAY® Pneumonia Panel Plus). Classical microbiological culture (CMC) will be considered the gold standard for microbiological pneumonia diagnosis. The agreement between the results of the Pneumonia Plus® panel and the results of conventional microbial culture (CMC) will be assessed.

An empiric antibiotic therapy will be prescribed according to the local ecology and the protocols of each ICU unit. Two senior experts in each participating center will have to approve the antibiotic prescription. The antibiotic therapy could be modified after the reception of the Mutilpex PCR results by the two senior experts. After the reception of the results of the classic microbiological culture, the previous antibiotic changes will be judged as appropriate or inappropriate by a multidisciplinary team including intensivists, infectious disease specialists, and microbiologists. Appropriate changes include adequacy, de-escalation, and optimization of antibiotic therapy, and inappropriate changes include inadequacy, escalation, and de-optimization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 210
• Est. completion date: February 22, 2024
• Est. primary completion date: February 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• critically ill adult patients

• clinical, biological, and radiological signs of severe pneumonia.

• community-acquired pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia

• invasive mechanical ventilation.

Exclusion Criteria:

• Non-invasive mechanical ventilation.

Related Conditions & MeSH terms

• Community-acquired Pneumonia
• Healthcare-Associated Pneumonia
• Hospital-acquired Pneumonia
• Pneumonia
• Pneumonia, Ventilator-Associated
• Ventilator Associated Pneumonia

Intervention

Diagnostic Test:
• Multiplex respiratory PCR
The BIOFIRE® FILMARRAY® Pneumonia plus Panel

Locations

Country	Name	City	State
Morocco	Avicenna Military Hospital	Marrakesh	Marrakesh Tensift El Haouz

Sponsors (1)

Lead Sponsor	Collaborator
Avicenna Military Hospital

Country where clinical trial is conducted

Morocco, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of diagnostic concordance between Classical microbiological cultures and the respiratory multiplex PCR (RM-PCR) and conventional microbiological cultures (CMC) to identify pathogens responsible for severe pneumonia in critically ill patients.	Classical microbiological cultures (CMC) will serve as the gold standard for the comparison between techniques, considering a test result: A true positive, when CMC and RM-PCR have identified the same microorganism (CMC+, PCR-RM +).; A false positive, when RM-PCR detected an organism but not CMC (CMC-, RM-PCR+); A true negative, when no method detected any microorganism (CMC-, RM-PCR -); A false negative, when CMC but not RM-PCR has detected an organism (CMC+, RM-PCR -).; Sensitivity, specificity, and positive and negative predictive values for the respiratory multiplex PCR will be calculated using the precedent findings.	through study completion, an average of 6 months
Primary	The impact of the respiratory multiplex PCR (RM-PCR) on the appropriateness of empirical antimicrobial therapy.	The proportion of patients for whom the respiratory multiplex PCR (RM-PCR) induces an appropriate change of antibiotic therapy. Appropriate changes include adequacy, de-escalation, and escalation of antibiotic treatment.; Adequacy is defined as introducing an antibiotic to cover a microorganism that was not adequately treated before the results of RM-PCR.; Escalation is defined by a widening of the ATB spectrum to cover a pathogen not taken into account or the detection of resistance genes.; De-escalation is defined as the use of a narrower-spectrum anti-infective or the discontinuation of an ATB combination.	through study completion, an average of 6 months